[1]谢 旭,李国焕,贾文燕,等.参芪软肝汤配合抗病毒药物治疗肝硬化临床研究[J].陕西中医,2024,(6):771-774.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.010]
　XIE Xu,LI Guohuan,JIA Wenyan,et al.Shenqi Ruangan decoction combined with antiviral drugs in the treatment of liver cirrhosis[J].,2024,(6):771-774.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.010]
点击复制

参芪软肝汤配合抗病毒药物治疗肝硬化临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
771-774
栏目:
临床研究
出版日期:
2024-06-05

文章信息/Info

Title:
Shenqi Ruangan decoction combined with antiviral drugs in the treatment of liver cirrhosis
作者:
谢 旭; 李国焕; 贾文燕; 张铭业; 徐文婷; 谭万芳
(珠海市中西医结合医院感染性疾病科,广东 珠海 519000)
Author(s):
XIE Xu; LI Guohuan; JIA Wenyan; ZHANG Mingye; XU Wenting; TAN Wanfang
(Infectious Diseases Department of Zhuhai Integrated Traditional Chinese and Western Medicine Hospital,Zhuhai 519000,China)
关键词:
肝硬化;  参芪软肝汤;  富马酸丙酚替诺福韦片;  肝功能;  中医症候;  肝纤维化
Keywords:
Liver cirrhosis;  Shenqi Ruangan decoction;  Profol tenofovir fumarate tablets;  Liver function;  Symptoms of traditional Chinese medicine;  Hepatic fibrosis
分类号:
R 575.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.06.010
文献标志码:
A
摘要:
目的:探索参芪软肝汤配合抗病毒药物防治肝硬化的临床疗效。方法:选取90例肝硬化患者,将其分为观察组和对照组各45例。对照组以常规抗病毒治疗,观察组增加参芪软肝汤治疗。评估对比两组患者的临床疗效、中医症候积分、肝功能指标、肝纤维化指标、肝组织病理变化、治疗安全性等指标。结果:观察组总有效率为91.11%,高于对照组的73.33%(P<0.05)。治疗后,观察组中医症候积分包括胁肋隐痛、倦怠乏力、口眼干涩、身目黄染评分均低于对照组(P<0.05)。观察组直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷氨酰转移酶(GGT)、胆汁酸(TBA)低于对照组(P<0.05)。治疗后,观察组血清透明质酸(HA)、Ⅳ 型胶原(Ⅳ-C)、Ⅲ型前胶原N端肽(PⅢPN-P)、层粘连蛋白(LN)水平低于对照组(P<0.05)。治疗后,观察组肝组织病理变化炎症分级、纤维化分期均优于对照组(P<0.05)。治疗期间两组不良反应发生率为15.56%、11.11%,两组比较差异无统计学意义(P>0.05)。结论:参芪软肝汤用于防治肝硬化效果较好,可减轻中医症候程度,降低肝功能及肝纤维化水平,改善肝组织病理状态,治疗安全性良好。
Abstract:
Objective:To explore the clinical efficacy of Shenqi Ruangan decoction combined with antiviral drugs in prevention and treatment of cirrhosis.Methods:A total of 90 patients with cirrhosis were divided into observation group and control group,45 cases in each group.The control group was treated with conventional antiviral therapy,and the observation group was treated with Shenqi Ruangan decoction.The clinical efficacy,symptoms of traditional Chinese medicine,liver function indexes,liver fibrosis indexes,pathological changes of liver tissue,and treatment safety indexes of the two groups were evaluated and compared.Results:The total effective rate of observation group was 91.11%,which was higher than 73.33% in control group(P<0.05).After treatment,the scores of TCM symptoms in the observation group were lower than those in the control group(P<0.05),including dull pain in the hypochondrium,fatigue and fatigue,dry mouth and eyes,and yellow eye staining.Direct bilirubin(DBIL),alanine aminotransferase(ALT),glutamyltransferase(GGT)and bile acid(TBA)in observation group were lower than those in control group(P<0.05).After treatment,the serum levels of HA,Ⅳ-C,PⅢPN-P and LN in observation group were lower than those in control group(P<0.05).After treatment,the pathological changes of liver tissue inflammation grade and fibrosis stage in the observation group were better than those in the control group(P<0.05).The incidence of adverse reactions between the two groups was 15.56% and 11.11%,and there was no significant difference between the two groups(P>0.05).Conclusion:Shenqi Ruangan decoction is effective in preventing and treating liver cirrhosis.It can reduce the symptoms of traditional Chinese medicine,reduce liver function and liver fibrosis,and improve the pathological status of liver tissue.

参考文献/References:

[1] GINES P,KRAG A,ABRALDES J G,et al.Liver cirrhosis[J].Lancet,2021,38(8):1359-1376.
[2] 唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,43(10):1359-1363.
[3] ENGELMANN C,CLARIA J,SZABO G,et al.Pathophysiology of decompensated cirrhosis:Portal hypertension,circulatory dysfunction,inflammation,metabolism and mitochondrial dysfunction[J].J Hepatol,2021,75(1):49-66.
[4] 张燕洁,李晓玲,张莹雪,等.健脾活血利水法治疗肝硬化腹水Meta分析[J].陕西中医,2023,44(6):801-807.
[5] 庄焱.血管性血友病因子抗原与VITRO评分对乙型肝炎肝硬化预后的预测价值[J].陕西医学杂志,2023,52(8):1059-1062.
[6] 葛舰,李小丹,王祖君,等.基于数据挖掘分析中医药治疗肝硬化腹水与肝硬化顽固性腹水用药规律的异同[J].中西医结合肝病杂志,2022,32(4):511-515.
[7] 黄鸿娜,钟跃学,王小娇,等.基于鳖甲煎丸方药配伍规律探讨肝硬化的中医治疗[J].广西中医药大学学报,2022,25(1):1025-1030.
[8] 中国中西医结合学会消化系统疾病专业委员会.肝硬化中西医结合诊疗共识[J].中国中西医结合消化杂志,2011,19(4):277-279.
[9] 李军祥,陈誩,姚树坤.肝纤维化中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(12):895-900.
[10] 高淑娟,张蓉,郭雪艳,等.门脉CT血管成像联合内镜治疗肝硬化食管胃静脉曲张应用价值研究[J].陕西医学杂志,2021,50(7):807-810.
[11] 赵伟贤,麦燕华,蔡玉玲.连续性护理管理对乙肝肝硬化失代偿患者抗病毒治疗的依从性与预后影响[J].河北医药,2021,43(16):411-414.
[12] YANG X,LI Q,LIU W,et al.Mesenchymal stromal cells in hepatic fibrosis/cirrhosis:From pathogenesis to treatment[J].Cell Mol Immunol,2023,20(6):583-599.
[13] 王木源,李小科,刘蕊洁,等.基于文献分析探讨中医药治疗乙型肝炎肝硬化腹水的用药特点[J].中西医结合肝病杂志,2021,29(11):282-286.
[14] 袁维,孙克伟,陈斌,等.鳖龙软肝汤抗肝纤维化-肝癌“多成分-多靶点”的网络药理学研究[J].中西医结合肝病杂志,2022,32(4):611-616.
[15] 谭华梁,肖麟,李珍.鳖龙软肝汤对肝癌细胞增殖,凋亡及Bcl-2/CytC信号通路的影响[J].时珍国医国药,2022,33(4):1033-1036.
[16] 郑希妮.降脂疏肝汤治疗非酒精性脂肪性肝病的临床疗效观察[J].中国中医药科技,2021,28(1):211-213.
[17] 何秀敏,肖怀葱,陈利清.解郁疏肝汤联合瑞舒伐他汀治疗对非酒精性脂肪性肝病患者血脂、肝功能及炎性因子指标的影响[J].内蒙古中医药,2022,41(7):42-43.
[18] 冯颖,时克,张晓华,等.抗肝纤维化中药治疗对肝硬化并发肠系膜上静脉栓塞患者预后的影响[J].临床肝胆病杂志,2022,38(7):611-616.
[19] YAO L,HU X,DAI K,et al.Mesenchymal stromal cells:Promising treatment for liver cirrhosis[J].Stem Cell Res Ther,2022,13(1):308-312.
[20] 侯维,孟庆华.肝硬化患者肌肉减少症的临床特点与发病机制研究进展[J].中西医结合肝病杂志,2021,31(5):611-616.
[21] 其七,姚欣,杨国栋,等.推荐用于乙肝肝硬化失代偿期病例抗病毒治疗药物的临床应用现状[J].国际病毒学杂志,2023,30(3):248-250.
[22] LEE N Y,SUK K T.The role of the gut microbiome in liver cirrhosis treatment[J].Int J Mol Sci,2020,28(1):199-202.
[23] 陈杰,高凌燕.软肝汤联合恩替卡韦治疗乙型病毒性肝炎肝硬化腹水临床观察[J].中国药业,2023,32(3):94-97.
[24] 殷光辉.化瘀软肝汤对代偿期乙型病毒性肝炎肝硬化的疗效分析[J].深圳中西医结合杂志,2020,30(13):123-125.
[25] 訾璐,徐艺,王玉,等.利水软肝汤、中药敷脐联合温针灸对肝硬化腹水患者肝功能、尿量和门静脉血流动力学的影响[J].中西医结合肝病杂志,2021,31(1):40-43.

相似文献/References:

[1]傅琪琳,唐颖慧,黄 甫,等.理饮汤治疗肝硬化失代偿期并发肝性胸水疗效研究[J].陕西中医,2019,(6):733.
　FU Qilin,TANG Yinghui,HUANG Fu,et al.Effecte of Liyin decoction adjuvant treatment in decompensated cirrhosis with hepatic pleural effusion[J].,2019,(6):733.
[2]田莉婷,刘雪萍,李丹妮,等.加味苓桂术甘汤对脾肾阳虚型肝硬化失代偿期患者生存率的影响*[J].陕西中医,2019,(10):1373.
　TIAN Liting,LIU Xueping,LI Danni,et al.Effect of Jiawei Lingui Shugan decoction on survival rate of patients with spleen，kidney and Yang deficiency type decompensated cirrhosis[J].,2019,(6):1373.
[3]聂姝常,王妙苗,程彬彬.肝硬化合并肠道功能失调的中西医结合治疗研究进展[J].陕西中医,2023,(2):259.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.028]
　NIE Shuchang,WANG Miaomiao,CHENG Binbin.Research progress of traditional Chinese and western medicine for treating intestinal dysfunction in liver cirrhosis[J].,2023,(6):259.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.028]
[4]王子宜,许明岩,王丽媛,等.芪甲软肝丸治疗肝硬化代偿期疗效研究[J].陕西中医,2024,(4):507.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.016]
　WANG Ziyi,XU Mingyan,WANG Liyuan,et al.Effect of Qijia Ruangan pill in the treatment of compensatory stage of liver cirrhosis[J].,2024,(6):507.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.016]
[5]刘博文,李晓斌,马贵萍,等.名中医胡世平运用“培养、招纳、解散”三法治疗慢性肝病腹水经验[J].陕西中医,2024,(6):812.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.019]
　LIU Bowen,LI Xiaobin,MA Guiping,et al.Experience of Hu Shiping in treating ascites in chronic liver disease with the three methods of “cultivation,recruitment and dissolution”[J].,2024,(6):812.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.019]
[6]王鹏利,周小燕,王少辉,等.通腹逐瘀颗粒预防肝硬化脾切除术后门静脉血栓形成临床研究[J].陕西中医,2025,46(2):206.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.012]
　WANG Pengli,ZHOU Xiaoyan,WANG Shaohui,et al.Prevention of Tongfu Zhuyu granules on portal vein thrombosis after splenectomy in liver cirrhosis[J].,2025,46(6):206.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.012]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82304927); 广东省中医药局科研课题(20232161)
更新日期/Last Update: 2024-06-11